Profile data is unavailable for this security.
About the company
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Company's lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader being developed for the treatment of Non-Hodgkins Lymphoma. SP-3164 is a small molecule protein degrader, and seclidemstat (SP-2577) is a small molecule inhibitor. SP-3164 is a next-generation cereblon-binding molecular glue (MG). SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold. The molecule was discovered using structure-based computational screening coupled with chemical screening and further optimization with structure-activity relationship studies.
- Revenue in USD (TTM)0.00
- Net income in USD-8.92m
- Incorporated2014
- Employees2.00
- LocationSalarius Pharmaceuticals Inc2450 Holcombe Blvd Ste J-608HOUSTON 77021-2041United StatesUSA
- Phone+1 (617) 874-1821
- Fax+1 (302) 655-5049
- Websitehttps://salariuspharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GRI Bio Inc | 0.00 | -12.77m | 947.93k | 4.00 | -- | 0.138 | -- | -- | -349.68 | -349.68 | 0.00 | 11.38 | 0.00 | -- | -- | 0.00 | -382.23 | -192.93 | -869.57 | -353.99 | -- | -- | -- | -37,650.49 | -- | -16.80 | 0.00 | -- | -- | -- | -85.61 | -- | 29.46 | -- |
| Herborium Group, Inc. | 340.33k | -318.65k | 1.09m | 2.00 | -- | -- | -- | 3.21 | -0.3492 | -0.3492 | 0.3672 | -1.16 | 2.32 | 3.89 | 25.94 | -- | -216.97 | -490.56 | -- | -- | 58.31 | 56.36 | -93.63 | -186.81 | 0.0331 | -39.14 | -- | -- | 19.45 | -18.15 | 120.44 | -- | -- | -- |
| LadRx Corp | 0.00 | 1.66m | 1.11m | 2.00 | 0.6504 | 3.21 | 0.663 | -- | 3.44 | 3.44 | 0.00 | 0.6973 | 0.00 | -- | -- | 0.00 | 96.28 | -58.97 | -- | -78.44 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 106.96 | -- | -- | -- |
| Actavia Life Sciences Inc | 0.00 | -406.65k | 1.23m | 1.00 | -- | -- | -- | -- | -0.0005 | -0.0005 | 0.00 | -0.0028 | 0.00 | -- | -- | 0.00 | -805.97 | -158.17 | -- | -- | -- | -- | -- | -- | -- | -5.63 | -- | -- | -- | -- | -547.04 | -- | -- | -- |
| Dermata Therapeutics Inc | 0.00 | -8.69m | 1.33m | 8.00 | -- | 4.13 | -- | -- | -24.67 | -24.67 | 0.00 | 0.5717 | 0.00 | -- | -- | 0.00 | -120.05 | -- | -146.08 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.90 | -- | -- | -- |
| Salarius Pharmaceuticals Inc | 0.00 | -8.92m | 1.36m | 2.00 | -- | 0.3362 | -- | -- | -21.71 | -21.71 | 0.00 | 6.77 | 0.00 | -- | -- | 0.00 | -119.38 | -69.27 | -193.68 | -79.89 | -- | -- | -- | -675.70 | -- | -- | 0.031 | -- | -- | -- | 60.32 | -- | -- | -- |
| Manuka Inc | 671.00k | -1.14m | 1.46m | 4.00 | -- | -- | -- | 2.17 | -0.0128 | -0.0128 | 0.0066 | -0.0124 | 2.41 | 0.9412 | 37.28 | 167,750.00 | -410.43 | -463.75 | -- | -- | 88.08 | -- | -170.04 | -732.15 | 0.0194 | -- | -- | -- | -- | -- | -854.23 | -- | -- | -- |
| 180 Life Sciences Corp | 0.00 | -16.24m | 1.47m | 4.00 | -- | -- | -- | -- | -41.54 | -41.54 | 0.00 | -1.12 | 0.00 | -- | -- | 0.00 | -176.90 | -42.39 | -354.57 | -56.41 | -- | -- | -- | -- | -- | -385.88 | -- | -- | -- | -- | 48.52 | -- | -- | -- |
| Drazcanna Inc | 2.05m | -5.71m | 1.47m | -- | -- | -- | -- | 0.7192 | -0.7024 | -0.7024 | 0.2492 | 0.1004 | 0.685 | -- | 23.88 | -- | -191.19 | -- | -643.20 | -- | -11.20 | -- | -279.10 | -- | -- | -33.04 | 0.2445 | -- | -- | -- | -- | -- | -- | -- |
| Virpax Pharmaceuticals Inc | 0.00 | -16.89m | 1.58m | 7.00 | -- | -- | -- | -- | -14.42 | -14.42 | 0.00 | -1.04 | 0.00 | -- | -- | 0.00 | -156.21 | -87.52 | -241.52 | -116.56 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.84 | -- | -- | -- |
| Seelos Therapeutics Inc | 1.97m | -27.12m | 1.59m | 10.00 | -- | -- | -- | 0.804 | -44.59 | -44.59 | 2.16 | -17.36 | 0.1449 | -- | 2.24 | 131,600.00 | -198.99 | -180.05 | -- | -386.76 | -- | -- | -1,373.61 | -9,612.88 | -- | -- | -- | -- | -- | -- | 48.48 | -- | -- | -- |
| CNS Pharmaceuticals Inc | 0.00 | -17.46m | 1.76m | 3.00 | -- | -- | -- | -- | -179.17 | -179.17 | 0.00 | -20.76 | 0.00 | -- | -- | 0.00 | -384.86 | -132.47 | -- | -185.75 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -23.42 | -- | -- | -- |
| Hi-Great Group Holding Co | 101.27k | -113.56k | 1.78m | -- | -- | -- | -- | 17.58 | -0.0011 | -0.0011 | 0.001 | -0.0011 | 0.7887 | 0.8027 | -- | -- | -88.44 | -- | -- | -- | 48.60 | -- | -112.14 | -- | 0.0197 | -48.81 | -- | -- | -47.32 | -- | -3,789.70 | -- | -- | -- |
| Panbela Therapeutics Inc | 0.00 | -27.26m | 1.78m | 7.00 | -- | -- | -- | -- | -20.38 | -20.38 | 0.00 | -0.6563 | 0.00 | -- | -- | 0.00 | -201.94 | -215.89 | -809.38 | -476.38 | -- | -- | -- | -- | -- | -161.79 | 4.16 | -- | -- | -- | 27.68 | -- | -- | -- |
